You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

~ Buy the SYNJARDY (empagliflozin; metformin hydrochloride) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR SYNJARDY

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for synjardy

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05132023 ↗	Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)	Completed	Hikma Pharma	Phase 1	2019-03-26	Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Empagliflozin & Metformin HCL from Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)
NCT05132023 ↗	Bioequivalence Study of Empagliflozin & Metformin HCL From Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)	Completed	Genuine Research Center, Egypt	Phase 1	2019-03-26	Comparative randomized, single dose, two-way crossover open-label study to determine the bioequivalence of Empagliflozin & Metformin HCL from Empagliform 12.5/1000 mg F.C.T (Hikma Pharma, Egypt) and Synjardy 12.5/1000 mg F.C.T (Boehringer Ingelheim International GmbH, Germany)
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for synjardy

Condition Name

Chart
Table

Condition Name for synjardy
Intervention	Trials
Healthy	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for synjardy
Intervention	Trials
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for synjardy

Trials by Country

Map
Table

Trials by Country for synjardy
Location	Trials
Egypt	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for synjardy

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for synjardy
Clinical Trial Phase	Trials
Phase 1	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for synjardy
Clinical Trial Phase	Trials
Completed	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for synjardy

Sponsor Name

Chart
Table

Sponsor Name for synjardy
Sponsor	Trials
Hikma Pharma	1
Genuine Research Center, Egypt	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for synjardy
Sponsor	Trials
Other	1
Industry	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.